Biosimilar Cell Lines

Ready to go, high expressing manufacturing biosimilar cell lines ready for development

Polpharma Biologics has developed a portfolio of high producing cell lines expressing biosimilar proteins, such as fusion proteins, enzymes and monoclonal antibodies which are available for out-licensing.

These biosimilar cell lines are generated on our proprietary CHO-based platform, CHOBC® using (animal component free) of the shelf culture medium. The cell lines are GMP-ready, stable, high producing, fully documented and functionally characterized. All available QA approved documentation is accessible for our (potential) partners via a Virtual Data Room.

Biosimilar programs are ready for tech transfer to a CMO of your choice or you can use our own CDMO services to advance to the clinic rapidly. Our cell lines and programs in different development stages, can be found in the table below. If a biosimilar that you are interested in is not listed contact us as we may have it in late stage development or can develop a cell line for you.

Cell Lines Available Today

Biosimilar toAntibody
Herceptin®Trastuzumab
Humira®Adalimumab
Erbitux®Cetuximab
Avastin®Bevacizumab
Rituxan/MabThera®Rituximab
Enbrel®Etanercept
Synagis®Palivizumab
Xolair®Omalizumab
Yervoy®Ipilimumab
Perjeta®Pertuzumab
Opdivo®Nivolumab
Keytruda®Pembrolizumab

For more information, licensing terms and purchase options please contact us.

Biosimilars

Cell Line Development

We take a different approach to other companies when developing biosimilar cell lines, we focus on delivering high titer cell lines and then tailoring modulation to match the given quality target product profile.

Biosimilars

Analytics & Bioassays

We have the most extensive bioanalytical and bioassay toolbox to ensure and test biosimilarity with originator therapeutics.

Biosimilars

Process Development

Our biosimilar process development focuses on quality and reducing cost. We know that it is critical to reduce overall cost of goods and the way we design our processes increases titer without increasing media and feed requirements.

Biosimilars

Manufacturing

We provide Drug Substance and Drug Product manufacturing for clinical and commercial supply at our cGMP facilities, including fill & finish.